Tumors in the stomach and pancreas are known to express claudin 18.2 (CLDN18.2) and the absence of expression in normal tissues makes it an attractive therapeutic target.
In a panel discussion with executives at the 2024 BIO CEO conference this week in New York, the consensus emerged that artificial intelligence is here to stay, despite its occasional moments of hype, as its applications continually grow.
The transcription of ribosomal RNA by RNA Polymerase I (Pol I) is an essential step for cells to grow and thus is considered a therapeutic target for cancer treatment.
Claudin-6 (CLDN6) is highly expressed in several cancer types, including ovarian and endometrial cancers, while very low or no expression is found in normal tissues.
Researchers from Capital Medical University have presented preclinical data for the novel PDZ-binding kinase (PBK) inhibitor, HI-TOPK-032, which is being developed for the treatment of cancer. The study aimed to assess the effects of the candidate on NK-92MI cell infiltration into ovarian tumors.
Biocom California’s Global Life Science Partnering & Investor Conference kicked off with a panel discussion focused on artificial intelligence (AI) in drug discovery. While there’s been a lot of hype over how AI and machine learning have the potential to help companies speed up drug development, panelists hypothesized the largest opportunities are in developing new capabilities, potentially increasing the success rate going from discovery to regulatory approval.
PARP inhibitors such as olaparib are used for the treatment of metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination deficiency (HRD), but a proportion of these patients do not respond to therapy or eventually develop resistance.
Mutations in both KRAS and BRAF oncogenes, which are frequently found in colorectal cancer, are associated with poor prognosis and treatment resistance.
RSS
